The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia
Open accessAbstract
The role of androgens in cardiovascular disease is uncertain. We aimed to determine the vascular effects of androgen suppression in men with prostate cancer. Arterial stiffness (or ‘compliance’) was measured in 16 men (71±9 years, mean±S.D.) prior to, and 3 months after, complete androgen suppression with gonadotrophin-releasing hormone analogues as treatment for prostate cancer. Fifteen control men (70±7 years) also had arterial stiffness studies at baseline and 3 months later. Two measures of arterial stiffness were employed: systemic arterial compliance (SAC) was measured by simultaneous recording of aortic flow and carotid artery pressure (‘area method’), and pulse wave velocities (PWVs) were recorded with the ‘Complior’ system. The 16 cases underwent glucose-tolerance and fasting-lipids tests on both visits. After 3 months of testosterone suppression, there was a significant fall in SAC, which was not seen in the controls [mean change±S.E.M., -0.26±0.09a.c.u. (arbitrary compliance unit) in the cases versus +0.06±0.11 in the controls; P = 0.03). Central, but not peripheral, PWVs tended to increase in the cases (mean change±S.E.M. for aorto-femoral PWV, +0.5±0.4m/s for cases versus -0.3±0.3m/s for controls; P = 0.08). After testosterone suppression, fasting insulin levels increased from 6.89±4.84m-units/l to 11.34±8.16m-units/l (mean±S.D.), total cholesterol increased from 5.32±0.77mmol/l to 5.71±0.82mmol/l and high-density lipoprotein cholesterol increased from 1.05±0.24mmol/l to 1.26±0.36mmol/l; P<0.005 for all. No significant change occurred in body-mass index, serum glucose, low-density lipoprotein cholesterol or triacylglycerol (triglyceride) levels. Our results indicate that loss of androgens in men leads to an increase in aortic stiffness and serum insulin levels, and may therefore adversely affect cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laurent, S., Boutouyrie, P., Asmar, R., Gautier, I., Laloux, B., Guize, L., Ducimetiere, P., & Benetos, A. (2001) · Hypertension · doi:10.1161/01.hyp.37.5.1236 · Cited by 3,856
Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients
Blacher, J., Asmar, R., Djane, S., London, G. M., & Safar, M. E. (1999) · Hypertension · doi:10.1161/01.hyp.33.5.1111 · Cited by 1,493
Asmar, R., Benetos, A., Topouchian, J., Laurent, P., Pannier, B., Brisac, A.-M., Target, R., & Levy, B. I. (1995) · Hypertension · doi:10.1161/01.hyp.26.3.485 · Cited by 1,376
Stellato, R. K., Feldman, H. A., Hamdy, O., Horton, E. S., & McKinlay, J. B. (2000) · Diabetes Care · doi:10.2337/diacare.23.4.490 · Cited by 618
Salomaa, V., Riley, W., Kark, J. D., Nardo, C., & Folsom, A. R. (1995) · Circulation · doi:10.1161/01.cir.91.5.1432 · Cited by 582
Collins, P., Rosano, G. M. C., Sarrel, P. M., Ulrich, L., Adamopoulos, S., Beale, C. M., McNeill, J. G., & Poole-Wilson, P. A. (1995) · Circulation · doi:10.1161/01.cir.92.1.24 · Cited by 530
Androgens in Men — Uses and Abuses
Bagatell, C. J., & Bremner, W. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341107 · Cited by 464
Hanson, R. L., Pratley, R. E., Bogardus, C., Narayan, K. M. V., Roumain, J. M. L., Imperatore, G., Fagot-Campagna, A., Pettitt, D. J., Bennett, P. H., & Knowler, W. C. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010187 · Cited by 463
Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockcroft, J. R., Scanlon, M. F., & Davies, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7851 · Cited by 458
Effects of Testosterone on Coronary Vasomotor Regulation in Men With Coronary Heart Disease
Webb, C. M., McNeill, J. G., Hayward, C. S., de Zeigler, D., & Collins, P. (1999) · Circulation · doi:10.1161/01.cir.100.16.1690 · Cited by 451
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791
“Two studies have shown an increase in insulin levels in patients treated with gonadotrophinreleasing hormone (GnRH) agonists ( 14 , 15).”
BackgroundMetabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., & Basaria, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9741 · Cited by 585
Testosterone: a metabolic hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0455 · Cited by 577
Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men
Pitteloud, N., Mootha, V. K., Dwyer, A. A., Hardin, M., Lee, H., Eriksson, K.-F., Tripathy, D., Yialamas, M., Groop, L., Elahi, D., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1636 · Cited by 472
Basaria, S., Muller, D. C., Carducci, M. A., Egan, J., & Dobs, A. S. (2006) · Cancer · doi:10.1002/cncr.21642 · Cited by 394
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Androgens, insulin resistance and vascular disease in men
Kapoor, D., Malkin, C. J., Channer, K. S., & Jones, T. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02299.x · Cited by 317
Jani, B., & Rajkumar, C. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.036053 · Cited by 308
Self-citationTestosterone: a vascular hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0582 · Cited by 293
Sex differences in mechanisms of arterial stiffness
DuPont, J. J., Kenney, R. M., Patel, A. R., & Jaffe, I. Z. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14624 · Cited by 290
The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance
Traish, A. M., Saad, F., & Guay, A. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.005751 · Cited by 266
O'Farrell, S., Garmo, H., Holmberg, L., Adolfsson, J., Stattin, P., & Van Hemelrijck, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1792 · Cited by 265
Bosco, C., Bosnyak, Z., Malmberg, A., Adolfsson, J., Keating, N. L., & Van Hemelrijck, M. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.039 · Cited by 262
Yialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., & Hayes, F. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0454 · Cited by 220
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., Zakai, N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20061 · Cited by 188
Traish, A. M., Haider, A., Haider, K. S., Doros, G., & Saad, F. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417691136 · Cited by 130
Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men
Yaron, M., Greenman, Y., Rosenfeld, J. B., Izkhakov, E., Limor, R., Osher, E., Shenkerman, G., Tordjman, K., & Stern, N. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0052 · Cited by 78
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Darwish-Yassine, M., Berenji, M., Wing, D., Copeland, G., Demers, R. Y., Garlinghouse, C., Fagerlin, A., Newth, G. E., Northouse, L., Holmes-Rovner, M., et al. (2014) · Journal of Cancer Survivorship · doi:10.1007/s11764-013-0312-8 · Cited by 55
The Emerging Link Between Hypogonadism and Metabolic Syndrome
Guay, A. T. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.006015 · Cited by 50
Metadata
- Authors
- DOCKERY, F., BULPITT, C. J., AGARWAL, S., DONALDSON, M., & RAJKUMAR, C.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2003-01-17
- Volume
- 104
- Issue
- 2
- Pages
- 195-201
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2011581813
- Cited by
- 294
- References
- 36
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.